TREATMENT WITH INTRAVENOUS IMMUNOGLOBULIN G (IgGiv).IMMUNOMODULATION REPRODUCTIVE FAILURES
Abstract: Approved uses of intravenous IgG suspensions (IgGiv) are agammaglobulinemias, immune thrombocytopenia, rheumatoid arthritis, Guillán-Barré syndrome, myasthenia gravis, multiple sclerosis. IgGiv is proposed as an immunomodulatory agent in reproductive failures since it has been used to eval...
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Artículo revista |
| Lenguaje: | Español |
| Publicado: |
Escuela de Salud Pública y Ambiente. Fac. Cs. Médicas UNC
2017
|
| Materias: | |
| Acceso en línea: | https://revistas.unc.edu.ar/index.php/RSD/article/view/17144 |
| Aporte de: |
| id |
I10-R360-article-17144 |
|---|---|
| record_format |
ojs |
| institution |
Universidad Nacional de Córdoba |
| institution_str |
I-10 |
| repository_str |
R-360 |
| container_title_str |
Revista de Salud Pública |
| language |
Español |
| format |
Artículo revista |
| topic |
reproductive failure intravenous immunoglobulin G off-label use pharmacovigilance. fallas reproductivas inmunoglobulina G endovenosa uso “off label” farmacovigilancia falhas reprodutivas imunoglobulina intravenosa G Uso fora do rótulo farmacovigilância |
| spellingShingle |
reproductive failure intravenous immunoglobulin G off-label use pharmacovigilance. fallas reproductivas inmunoglobulina G endovenosa uso “off label” farmacovigilancia falhas reprodutivas imunoglobulina intravenosa G Uso fora do rótulo farmacovigilância Fontana, Daniela Feldman, Ester Torno, Aldana Massa, Catalina Barros, Carolina Rivero, Roxana Joekes, Silvia Mazzolli, Alicia Korteban, Graciela TREATMENT WITH INTRAVENOUS IMMUNOGLOBULIN G (IgGiv).IMMUNOMODULATION REPRODUCTIVE FAILURES |
| topic_facet |
reproductive failure intravenous immunoglobulin G off-label use pharmacovigilance. fallas reproductivas inmunoglobulina G endovenosa uso “off label” farmacovigilancia falhas reprodutivas imunoglobulina intravenosa G Uso fora do rótulo farmacovigilância |
| author |
Fontana, Daniela Feldman, Ester Torno, Aldana Massa, Catalina Barros, Carolina Rivero, Roxana Joekes, Silvia Mazzolli, Alicia Korteban, Graciela |
| author_facet |
Fontana, Daniela Feldman, Ester Torno, Aldana Massa, Catalina Barros, Carolina Rivero, Roxana Joekes, Silvia Mazzolli, Alicia Korteban, Graciela |
| author_sort |
Fontana, Daniela |
| title |
TREATMENT WITH INTRAVENOUS IMMUNOGLOBULIN G (IgGiv).IMMUNOMODULATION REPRODUCTIVE FAILURES |
| title_short |
TREATMENT WITH INTRAVENOUS IMMUNOGLOBULIN G (IgGiv).IMMUNOMODULATION REPRODUCTIVE FAILURES |
| title_full |
TREATMENT WITH INTRAVENOUS IMMUNOGLOBULIN G (IgGiv).IMMUNOMODULATION REPRODUCTIVE FAILURES |
| title_fullStr |
TREATMENT WITH INTRAVENOUS IMMUNOGLOBULIN G (IgGiv).IMMUNOMODULATION REPRODUCTIVE FAILURES |
| title_full_unstemmed |
TREATMENT WITH INTRAVENOUS IMMUNOGLOBULIN G (IgGiv).IMMUNOMODULATION REPRODUCTIVE FAILURES |
| title_sort |
treatment with intravenous immunoglobulin g (iggiv).immunomodulation reproductive failures |
| description |
Abstract: Approved uses of intravenous IgG suspensions (IgGiv) are agammaglobulinemias, immune thrombocytopenia, rheumatoid arthritis, Guillán-Barré syndrome, myasthenia gravis, multiple sclerosis. IgGiv is proposed as an immunomodulatory agent in reproductive failures since it has been used to evaluate rates of newborns in women with repeated failures in implantation (RFI) and recurrent abortions (RAb). However, this indication is not specified in the package leaflet (“off-label use”). Between 2010 and 2015, anamnesis and complete reproductive history were performed on 2333 couples, evaluating several factors. Of 447 pregnancies, 143 patients received IgGiv UNC treatment. 79 consulted for RAb (55%) and 64 for RFI (45%). The diagnosis of Hashimoto’s thyroiditis was positive in 91 patients (64%). In 3 patients (2%) there were adverse reactions. Live newborns were 83, success rate 58%. This high rate and the absence of adverse reactions are evidences of effectiveness and safety of IgGiv |
| publisher |
Escuela de Salud Pública y Ambiente. Fac. Cs. Médicas UNC |
| publishDate |
2017 |
| url |
https://revistas.unc.edu.ar/index.php/RSD/article/view/17144 |
| work_keys_str_mv |
AT fontanadaniela treatmentwithintravenousimmunoglobulingiggivimmunomodulationreproductivefailures AT feldmanester treatmentwithintravenousimmunoglobulingiggivimmunomodulationreproductivefailures AT tornoaldana treatmentwithintravenousimmunoglobulingiggivimmunomodulationreproductivefailures AT massacatalina treatmentwithintravenousimmunoglobulingiggivimmunomodulationreproductivefailures AT barroscarolina treatmentwithintravenousimmunoglobulingiggivimmunomodulationreproductivefailures AT riveroroxana treatmentwithintravenousimmunoglobulingiggivimmunomodulationreproductivefailures AT joekessilvia treatmentwithintravenousimmunoglobulingiggivimmunomodulationreproductivefailures AT mazzollialicia treatmentwithintravenousimmunoglobulingiggivimmunomodulationreproductivefailures AT kortebangraciela treatmentwithintravenousimmunoglobulingiggivimmunomodulationreproductivefailures AT fontanadaniela tratamientoconinmunoglobulinagintravenosalggivinmunomodulacionenfallasreproductivas AT feldmanester tratamientoconinmunoglobulinagintravenosalggivinmunomodulacionenfallasreproductivas AT tornoaldana tratamientoconinmunoglobulinagintravenosalggivinmunomodulacionenfallasreproductivas AT massacatalina tratamientoconinmunoglobulinagintravenosalggivinmunomodulacionenfallasreproductivas AT barroscarolina tratamientoconinmunoglobulinagintravenosalggivinmunomodulacionenfallasreproductivas AT riveroroxana tratamientoconinmunoglobulinagintravenosalggivinmunomodulacionenfallasreproductivas AT joekessilvia tratamientoconinmunoglobulinagintravenosalggivinmunomodulacionenfallasreproductivas AT mazzollialicia tratamientoconinmunoglobulinagintravenosalggivinmunomodulacionenfallasreproductivas AT kortebangraciela tratamientoconinmunoglobulinagintravenosalggivinmunomodulacionenfallasreproductivas AT fontanadaniela tratamentocominmunoglobulinagimintrutivaiggivmunomodulacaoemfalhasreprodutivas AT feldmanester tratamentocominmunoglobulinagimintrutivaiggivmunomodulacaoemfalhasreprodutivas AT tornoaldana tratamentocominmunoglobulinagimintrutivaiggivmunomodulacaoemfalhasreprodutivas AT massacatalina tratamentocominmunoglobulinagimintrutivaiggivmunomodulacaoemfalhasreprodutivas AT barroscarolina tratamentocominmunoglobulinagimintrutivaiggivmunomodulacaoemfalhasreprodutivas AT riveroroxana tratamentocominmunoglobulinagimintrutivaiggivmunomodulacaoemfalhasreprodutivas AT joekessilvia tratamentocominmunoglobulinagimintrutivaiggivmunomodulacaoemfalhasreprodutivas AT mazzollialicia tratamentocominmunoglobulinagimintrutivaiggivmunomodulacaoemfalhasreprodutivas AT kortebangraciela tratamentocominmunoglobulinagimintrutivaiggivmunomodulacaoemfalhasreprodutivas |
| first_indexed |
2024-09-03T22:26:28Z |
| last_indexed |
2025-05-10T05:21:28Z |
| _version_ |
1833249778906955776 |
| spelling |
I10-R360-article-171442025-04-03T12:06:25Z TREATMENT WITH INTRAVENOUS IMMUNOGLOBULIN G (IgGiv).IMMUNOMODULATION REPRODUCTIVE FAILURES Tratamiento con inmunoglobulina G intravenosa (lgGiv). Inmunomodulación en fallas reproductivas TRATAMENTO COM INMUNOGLOBULINA G IM INTRUTIVA (IgGiv) .MUNOMODULAÇÃO EM FALHAS REPRODUTIVAS Fontana, Daniela Feldman, Ester Torno, Aldana Massa, Catalina Barros, Carolina Rivero, Roxana Joekes, Silvia Mazzolli, Alicia Korteban, Graciela reproductive failure intravenous immunoglobulin G off-label use pharmacovigilance. fallas reproductivas inmunoglobulina G endovenosa uso “off label” farmacovigilancia falhas reprodutivas imunoglobulina intravenosa G Uso fora do rótulo farmacovigilância Abstract: Approved uses of intravenous IgG suspensions (IgGiv) are agammaglobulinemias, immune thrombocytopenia, rheumatoid arthritis, Guillán-Barré syndrome, myasthenia gravis, multiple sclerosis. IgGiv is proposed as an immunomodulatory agent in reproductive failures since it has been used to evaluate rates of newborns in women with repeated failures in implantation (RFI) and recurrent abortions (RAb). However, this indication is not specified in the package leaflet (“off-label use”). Between 2010 and 2015, anamnesis and complete reproductive history were performed on 2333 couples, evaluating several factors. Of 447 pregnancies, 143 patients received IgGiv UNC treatment. 79 consulted for RAb (55%) and 64 for RFI (45%). The diagnosis of Hashimoto’s thyroiditis was positive in 91 patients (64%). In 3 patients (2%) there were adverse reactions. Live newborns were 83, success rate 58%. This high rate and the absence of adverse reactions are evidences of effectiveness and safety of IgGiv Los principales usos aprobados de suspensiones de IgG intravenosa (IgGiv) son agamaglobulinemias, trombocitopenias inmunes, artritis reumatoidea, síndrome de Guillán-Barré, miastenia gravis, esclerosis múltiple. Se propone IgGiv como inmunomoduladora en fallas reproductivas ya que se utiliza para evaluar tasas de recién nacidos en mujeres con fallas reiteradas en implantación (FRI) y abortos recurrentes (AbR). Sin embargo, esta indicación no se especifica en el prospecto (“uso off-label”). Entre 2010 y 2015 se realizó anamnesis e historia clínica reproductiva completa a 2333 parejas evaluando varios factores. De 447 embarazos, 143 pacientes recibieron tratamiento con IgGiv UNC. 79 consultaron por AbR (55%) y 64 por FRI (45%). El diagnóstico de tiroiditis de Hashimoto fue positivo en 91 pacientes (64%). En 3 pacientes (2%) se observaron reacciones adversas. Los recién nacidos vivos fueron 83, tasa de éxito 58%. Esta alta tasa y la ausencia de reacciones adversas son evidencias de efectividad y seguridad de IgGiv. Resumo: Os principais usos aprovados das suspensões intravenosas de IgG (IgGiv) são agamaglobulinemias, trombocitopenia imune, artrite reumatóide, síndrome de Guillán-Barré, miastenia gravis, esclerose múltipla. IgGiv é proposto como um imuno-modulador em falhas reprodutivas, uma vez que é usado para avaliar as taxas de recém-nascidos em mulheres com falha repetida na implantação (FRI) e abortos recorrentes (AbR). No entanto, essa indicação não está especificada no prospecto off-label «). Entre 2010 e 2015, anamnesis e história reprodutiva completa foram realizadas em 2333 casais, avaliando vários fatores. De 447 gestações, 143 pacientes foram tratados com IgGivUNC.79 consultado para AbR (55%) e 64 para FRI (45%). O diagnóstico de tireoidite de Hashimoto foi positivo em 91 pacientes (64%). Foram observadas reações adversas em 3 pacientes (2%). Os recém-nascidos vivos eram 83, taxa de sucesso de 58%. Esta alta taxa e a ausência de reações adversas são evidências de eficácia e segurança de IgGiv Escuela de Salud Pública y Ambiente. Fac. Cs. Médicas UNC 2017-09-29 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion application/pdf https://revistas.unc.edu.ar/index.php/RSD/article/view/17144 10.31052/1853.1180.v21.n2.17144 Revista de Salud Pública; Vol. 21 Núm. 2 (2017): Revista de Salud Pública; 99-108 1852-9429 1853-1180 10.31052/1853.1180.v21.n2 spa https://revistas.unc.edu.ar/index.php/RSD/article/view/17144/17925 Derechos de autor 2017 Universidad Nacional de Córdoba https://creativecommons.org/licenses/by-nc/4.0 |